Literature DB >> 3407421

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years.

L H Lindström1.   

Abstract

A retrospective study was performed to evaluate the effect of long-term treatment with clozapine in 96 schizophrenic or schizoaffective patients hospitalized at the Psychiatric Research Center in Uppsala during the period 1974-1986. All patients had previously been treated with different neuroleptics but with inadequate response or distressing side effects. The mean duration of the disorder at the start of clozapine treatment was 8 years and 9 months and the mean duration of the treatment 3 years and 11 months. Clozapine treatment was discontinued in 36% of the patients, mainly due to lack of efficacy, poor compliance or temporary withdrawal of the drug from the market in 1975. In two patients the reason was leukopenia or agranulocytosis. In another 10 patients a transient decrement of WBC was seen, which was normalized during ongoing treatment. Four patients died when on clozapine during the follow-up period, but no causal relationship to the treatment could be established. Eighty-five per cent of the patients could be discharged from the hospital. Of the 62 patients who were still on clozapine after 2 years, 18% had full time and 21% half-time employment. A global evaluation of the clinical efficacy revealed a significant improvement in 43% and a moderate improvement in 38% of the patients compared to previous neuroleptic treatments. Common but usually mild side effects were sedation, hypersalivation, weight gain, and obstipation. Four patients had grand mal seizures. No extrapyramidal side effects were observed during clozapine treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3407421     DOI: 10.1111/j.1600-0447.1988.tb05164.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  39 in total

1.  Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients.

Authors:  D Naber; M Leppig; R Grohmann; H Hippius
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Clozapine in the treatment of 121 out-patients.

Authors:  M Leppig; B Bosch; D Naber; H Hippius
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Tolerability of long term clozapine treatment.

Authors:  M Schmauss; R Wolff; A Erfurth; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study.

Authors:  Yuan-Hwa Chou; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2006-01-05       Impact factor: 4.530

Review 5.  Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.

Authors:  J M Kane
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Management of schizophrenia : an update.

Authors:  P Kulhara
Journal:  Indian J Psychiatry       Date:  1998-04       Impact factor: 1.759

7.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

8.  Extrapyramidal side effects of clozapine and haloperidol.

Authors:  M Kurz; M Hummer; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 9.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 10.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.